REGENXBIO Announces Presentation at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

Rhea-AI Summary

REGENXBIO Inc. (Nasdaq: RGNX) announced it will participate in a fireside chat at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit on April 25, 2023, at 9:30 a.m. ET. The conference will occur in a virtual meeting format, with a live webcast accessible via the Investors section of REGENXBIO's website. An archived replay will be available for about 30 days post-event. REGENXBIO focuses on gene therapy, employing its NAV Technology Platform, which includes exclusive rights to over 100 AAV vectors. The company aims to progress five AAV Therapeutics from internal and licensed programs into pivotal or commercial products by 2025.

Positive

• Participation in a high-profile conference may enhance visibility and investor interest.
• REGENXBIO is advancing a significant gene therapy pipeline with a focus on commercializing products by 2025.

Negative

• None.

ROCKVILLE, Md., April 18, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will present in a fireside chat at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit on Tuesday, April 25, 2023 at 9:30 a.m. ET. The conference will be held in a virtual meeting format.

A live webcast of the fireside chat can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available in the Investors section of REGENXBIO's website for approximately 30 days following the fireside chat.

About REGENXBIO Inc.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8 and AAV9. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates, including late-stage and commercial programs, in multiple therapeutic areas. REGENXBIO is committed to a "5x'25" strategy to progress five AAV Therapeutics from our internal pipeline and licensed programs into pivotal-stage or commercial products by 2025.

Contacts:

Dana Cormack
Corporate Communications
dcormack@regenxbio.com 

Investors:
Chris Brinzey, ICR Westwicke
339-970-2843
chris.brinzey@westwicke.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-announces-presentation-at-chardans-7th-annual-genetic-medicines-and-cell-therapy-manufacturing-summit-301799830.html

SOURCE REGENXBIO Inc.

FAQ

What is the date of REGENXBIO's presentation at Chardan's summit?

REGENXBIO will present on April 25, 2023.

What time will REGENXBIO's fireside chat occur at the summit?

The fireside chat is scheduled for 9:30 a.m. ET.

Where can I watch the live webcast of REGENXBIO's presentation?

The live webcast can be accessed on REGENXBIO's Investors section of their website.

How long will the archived replay of REGENXBIO's presentation be available?

The archived replay will be available for approximately 30 days after the presentation.

What is REGENXBIO's strategy regarding their AAV Therapeutics?

REGENXBIO aims to progress five AAV Therapeutics into pivotal-stage or commercial products by 2025.